Stockchase Opinions

Bruce Campbell (2) Prometic Life Sciences Inc. PLI-T COMMENT Mar 10, 2017

Unless you have a really long term time horizon, you want to be pretty active in trading this. It tends to be volatile. It is probably currently at a time where you could Buy for the next trade up. There are going to be a lot of catalysts this year. It seemed to sell off hard late last year and early this year, and has bottomed and starting to move up. There will be a ton of news flow on this company. They are going to need to raise more money. Probably fully funded out until later this year or early next year, but at that point, they may have a drug approval, a royalty deal, etc., which might not necessarily come from an equity issue. They have a number of different irons in the fire and there are 3 or 4 that could be global blockbuster drugs. There is lots of opportunity long term, so you want to watch it, manage your position size, and trade around that.

$2.350

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

WATCH

He believes this has been very volatile due to an overhang and the potential need for more financing. It is stabilizing now and they have received an investment from the Thompson family. He thinks they should begin to receive approval soon with sales later this year. They do not own it presently, although they have held it in the past.

SELL

He is short this company presently. The market cap is quite high compared to his estimate of value. The company appears to be quite promotional compared to others. Their plasma protein product is easy to get through the FDA and subject to hype at each easy approval stage. He does not see revenues and earnings to back it up.

DON'T BUY

They have patents on plasma protein drugs that are interesting. The company had significant success pushing these through the FDA stages but they recently ran into a delay and the stock dropped precipitously. He has been short for a while thinking the market cap was overvalued for the ultimate end market they were pursuing. Now that the stock has dropped so much, his short position is smaller. This is a highly speculative position.

DON'T BUY

The key is their ability to take a bag of plasma and extract a bunch of proteins. They can sell as much as they can produce. The market is concerned about their spending in R&D. It appears to be a long way away from payday.

SELL
He has been disappointed in the company but in clinical trials and the FDA process, things don't go as well as you want. They ran into a cash crush so they extended the terms of their debt. It is way down and the time-frame is extended. You should move on. There is tax loss selling.
WAIT
The big challenge is getting their product to market. They have most of the cash they need into 2020, which should buy them enought time. He is watching to see how revenues ramp up next year.
SELL
He has followed this for a long time. It extracts protein from blood plasma and a drug that treats inflammation. They have added massive debt -- about $250 billion. He thinks there will be dramatic issues ahead and it will not end well for common shareholders.
DON'T BUY
The recent significant fall of 22% last week, would not be a signal to buy. He would stay away.
SELL
Technically, the new low at 8 cents does not offer anything meaningful. He would look at tax loss selling. Take the tax loss and move on.
DON'T BUY
They hit a financing crisis and needed cash. So, they issued 20 billion share at 1.5 cents per share. A massive dilution that destroyed the shareholder base. Avoid.